The Report is produced in Chinese only.
藥品工藝核查進一步利好龍頭 藥監局近日發佈《關於開展藥品生產工藝核對工作的公告》(徵求意見稿),規定對於已上市所有藥品進行工藝自查,限2016年10月1日前完成。自2016年11月1日起,國家局將啟動對藥品生產企業的飛行檢查。 可以預計的是,本次自查及飛檢將令生產工藝不過關的產品停產,同時有助於清理部分未銷售的僵屍批文。細分行業方面,我們認為中藥注射劑受影響較大,很多產品可能由於涉及工藝更改較多,將會面臨更大量的研究驗證工作。實際上,本次工藝核查將是藥監局繼臨床核查、藥品一致性評價之後的又一重磅改革措施,這將進一步利好規範生產的大型行業龍頭,部分不能完成工藝更改驗證研究的品種則面臨退市。個股方面,我們認為系列政策利好麗珠醫藥(1513 HK)、東陽光藥(1558 HK)、複星醫藥(2196 HK)等龍頭企業。 |
|
|
This report is produced and is being distributed in Hong Kong by Phillip Securities Group with the Securities and Futures Commission (“SFC”) licence under Phillip Securities (HK) LTD and/ or Phillip Commodities (HK) LTD (“Phillip”). Information contained herein is based on sources that Phillip believed to be accurate. Phillip does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The information is for informative purposes only and is not intended to or create/induce the creation of any binding legal relations. The information provided do not constitute investment advice, solicitation, purchase or sell any investment product(s). Investments are subject to investment risks including possible loss of the principal amount invested. You should refer to your Financial Advisor for investment advice based on your investment experience, financial situation, any of your particular needs and risk preference. For details of different product's risks, please visit the Risk Disclosures Statement on http://www.phillip.com.hk. Phillip (or employees) may have positions/ interests in relevant investment products. Phillip (or one of its affiliates) may from time to time provide services for, or solicit services or other business from, any company mentioned in this report. The above information is owned by Phillip and protected by copyright and intellectual property Laws. It may not be reproduced, distributed or published for any purpose without prior written consent from Phillip.